# EDGAR Filing Document

**Accession Number:** 0001865782
**File Stem:** 0001193125-25-253503
**Filing Date:** 2025-10
**Character Count:** 45564
**Document Hash:** a2eb79f6054e26ecd606bf90579e57ed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-253503.hdr.sgml**: 20251028

**ACCESSION NUMBER**: 0001193125-25-253503

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20251028

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251028

**DATE AS OF CHANGE**: 20251028

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BrightSpring Health Services, Inc.
- **CENTRAL INDEX KEY:** 0001865782
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 822956404
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41938
- **FILM NUMBER:** 251424895

**BUSINESS ADDRESS:**
- **STREET 1:** 805 N. WHITTINGTON PARKWAY
- **CITY:** LOUISVILLE
- **STATE:** KY
- **ZIP:** 40222
- **BUSINESS PHONE:** 502-394-2100

**MAIL ADDRESS:**
- **STREET 1:** 805 N. WHITTINGTON PARKWAY
- **CITY:** LOUISVILLE
- **STATE:** KY
- **ZIP:** 40222

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** October 28, 2025<br>

------

BrightSpring Health Services, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-41938 | 82-2956404 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 805 N. Whittington Parkway |  |  |
| Louisville**,** Kentucky |  | 40222 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 502 394-2100<br>

Not Applicable

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | BTSG | The Nasdaq Stock Market LLC |
| 6.75% Tangible Equity Units | BTSGU | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.
On October 28, 2025, BrightSpring Health Services, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated by specific reference in any such filing.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Description** |
| 99.1 | [<u>Press Release of BrightSpring Health Services, Inc., dated October 28, 2025.</u>](btsg-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | BRIGHTSPRING HEALTH SERVICES, INC. |
| Date: | October 28, 2025 | By:  | /s/ Jennifer Phipps |
|  |  | Name:<br>Title: | Jennifer Phipps<br>Executive Vice President and Chief Financial Officer |

---

------

## Exhibit 99.1

**BrightSpring Health Services, Inc. Reports Third Quarter 2025 Financial Results and Increases Full Year 2025 Guidance**

**LOUISVILLE, Ky., October 28, 2025** — BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the third quarter ended September 30, 2025, increased Revenue guidance, and reiterated Adjusted EBITDA<sup>1</sup> guidance.

**Financial Highlights**

*(note: all figures represent continuing operations and exclude the Community Living business)*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Revenues of $3,334 million, up 28.2% compared to $2,601 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Gross Profit of $392 million, up 21.3% compared to $323 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Third quarter net income of $37.5 million, compared to net loss of $25.7 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Adjusted EBITDA<sup>1</sup> of $160 million, up 37.2% compared to $117 million in the third quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Planned divestiture of Community Living business to Sevita, announced on January 20, 2025, is expected to close in Q1 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Kohlberg Kravis Roberts & Co, L.P. and certain members of management, offered for sale in a secondary offering an aggregate of 15,000,000 shares of common stock of BrightSpring, of which BrightSpring repurchased 1,500,000 shares. Both the offering and share repurchase closed on October 22, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Leverage was 3.31x, as calculated under our First Lien Credit Agreement at September 30, 2025. The results of the Community Living business are included in such calculation pursuant to our First Lien Credit Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Increased 2025 Revenue guidance and reiterated Adjusted EBITDA guidance, which excludes the Community Living business and the effects of any future closed acquisitions. All growth rates are shown as compared to the full year 2024 Revenue and Adjusted EBITDA results, excluding the Community Living business:

oRevenues of $12,500 million to $12,800 million, or 24.1% to 27.1% growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪Pharmacy Segment Revenue of $11,050 million to $11,300 million, or 26.2% to 29.1% growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;▪Provider Segment Revenue of $1,450 million to $1,500 million, or 10.0% to 13.8% growth.

oAdjusted EBITDA<sup>2</sup> of $605 million to $615 million, or 31.5% to 33.7% growth.

"We are pleased with our third quarter organizational results," said Jon Rousseau, Chairman, President, and Chief Executive Officer of the Company. "The performance in the quarter and ongoing progress throughout the year have been underpinned by our ability to deliver high-quality, patient-centric, and lower-cost care across the Pharmacy and Provider segments. We continue to focus on driving best practices in operations while leveraging our scale to provide quality and efficient services to complex populations in a timely, coordinated, and compassionate manner. We remain focused on executing at a high level towards BrightSpring's goals for the remainder of 2025 and into 2026."

------

**Preliminary Key Financials (for BrightSpring continuing operations)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** | &nbsp;&nbsp;**Three Months Ended** |  | &nbsp;&nbsp;**Nine Months Ended** | &nbsp;&nbsp;**Nine Months Ended** |  |
|  | &nbsp;&nbsp;**September 30, (Unaudited)** | &nbsp;&nbsp;**September 30, (Unaudited)** |  | &nbsp;&nbsp;**September 30, (Unaudited)** | &nbsp;&nbsp;**September 30, (Unaudited)** |  |
|  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** |
| &nbsp;&nbsp;($ in millions) |  |  |  |  |  |  |
| &nbsp;&nbsp;Pharmacy Solutions Revenue | &nbsp;&nbsp; $2967  | &nbsp;&nbsp; $2266  | &nbsp;&nbsp;31% | &nbsp;&nbsp; $8289  | &nbsp;&nbsp; $6357  | &nbsp;&nbsp;30% |
| &nbsp;&nbsp;Provider Services Revenue | &nbsp;&nbsp; 367  | &nbsp;&nbsp; 336  | &nbsp;&nbsp;9% | &nbsp;&nbsp; 1071  | &nbsp;&nbsp; 968  | &nbsp;&nbsp;11% |
| &nbsp;&nbsp; **Total Revenue** | &nbsp;&nbsp; **$3334**  | &nbsp;&nbsp; **$2601**  | &nbsp;&nbsp;**28%** | &nbsp;&nbsp; **$9360**  | &nbsp;&nbsp; **$7325**  | &nbsp;&nbsp;**28%** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** | &nbsp;&nbsp;**Three Months Ended** |  | &nbsp;&nbsp;**Nine Months Ended** | &nbsp;&nbsp;**Nine Months Ended** |  |
|  | &nbsp;&nbsp;**September 30, (Unaudited)** | &nbsp;&nbsp;**September 30, (Unaudited)** |  | &nbsp;&nbsp;**September 30, (Unaudited)** | &nbsp;&nbsp;**September 30, (Unaudited)** |  |
|  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** |
| &nbsp;&nbsp;($ in millions) |  |  |  |  |  |  |
| &nbsp;&nbsp;Pharmacy Solutions segment EBITDA  | &nbsp;&nbsp; $141  | &nbsp;&nbsp; $99  | &nbsp;&nbsp;42% | &nbsp;&nbsp; $381  | &nbsp;&nbsp; $282  | &nbsp;&nbsp;35% |
| &nbsp;&nbsp;Provider Services segment EBITDA | &nbsp;&nbsp; 61  | &nbsp;&nbsp; 52  | &nbsp;&nbsp;16% | &nbsp;&nbsp; 168 | &nbsp;&nbsp; 150  | &nbsp;&nbsp;12% |
| &nbsp;&nbsp;Total Segment Adjusted EBITDA | &nbsp;&nbsp; $202  | &nbsp;&nbsp; $151  | &nbsp;&nbsp;33% | &nbsp;&nbsp; $550  | &nbsp;&nbsp; $432  | &nbsp;&nbsp;27% |
| &nbsp;&nbsp;Corporate Costs | &nbsp;&nbsp;(42) | &nbsp;&nbsp;(34) | &nbsp;&nbsp;- | &nbsp;&nbsp;(116) | &nbsp;&nbsp;(102) | &nbsp;&nbsp;-  |
| &nbsp;&nbsp; **Total Company Adjusted EBITDA**<sup>(1)</sup> | &nbsp;&nbsp;**$160** | &nbsp;&nbsp; **$117**  | &nbsp;&nbsp;**37%** | &nbsp;&nbsp;**$434** | &nbsp;&nbsp; **$330**  | &nbsp;&nbsp;**32%** |

---

**Business Metrics**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | &nbsp;&nbsp;**Three Months Ended** | &nbsp;&nbsp;**Three Months Ended** |  | &nbsp;&nbsp;**Nine Months Ended** | &nbsp;&nbsp;**Nine Months Ended** |  |
|  | &nbsp;&nbsp;**September 30,** <br>**(Unaudited)** | &nbsp;&nbsp;**September 30,** <br>**(Unaudited)** |  | &nbsp;&nbsp;**September 30,** <br>**(Unaudited)** | &nbsp;&nbsp;**September 30,** <br>**(Unaudited)** |  |
|  | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** | &nbsp;&nbsp;**2025** | &nbsp;&nbsp;**2024** | &nbsp;&nbsp;**%** |
| &nbsp;&nbsp;**Pharmacy Solutions** |  |  |  |  |  |  |
| &nbsp;&nbsp;Prescriptions dispensed  | &nbsp;&nbsp;10793219 | &nbsp;&nbsp;10874429 | &nbsp;&nbsp;(1%) | &nbsp;&nbsp;32522286 | &nbsp;&nbsp;30849121 | &nbsp;&nbsp;5% |
| &nbsp;&nbsp;Revenue per script ($) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 274.89  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 208.35  | &nbsp;&nbsp;32% | &nbsp;&nbsp;254.88 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 206.07  | &nbsp;&nbsp;24% |
| &nbsp;&nbsp;Gross Profit per script ($) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22.76  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.34  | &nbsp;&nbsp;31% | &nbsp;&nbsp;21.01 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17.54  | &nbsp;&nbsp;20% |
| &nbsp;&nbsp;**Provider Services** |  |  |  |  |  |  |
| &nbsp;&nbsp;Home Health Care average <br>&nbsp;&nbsp;&nbsp;&nbsp;daily census | &nbsp;&nbsp;29592 | &nbsp;&nbsp;28650 | &nbsp;&nbsp;3% | &nbsp;&nbsp;29970 | &nbsp;&nbsp;28034 | &nbsp;&nbsp;7% |
| &nbsp;&nbsp;Rehab Care persons served | &nbsp;&nbsp;7321 | &nbsp;&nbsp;6571 | &nbsp;&nbsp;11% | &nbsp;&nbsp;7048 | &nbsp;&nbsp;6615 | &nbsp;&nbsp;7% |
| &nbsp;&nbsp;Personal Care persons served | &nbsp;&nbsp;16134 | &nbsp;&nbsp;15910 | &nbsp;&nbsp;1% | &nbsp;&nbsp;16046 | &nbsp;&nbsp;15880 | &nbsp;&nbsp;1% |

---

<sup>1</sup>Adjusted EBITDA is a non-GAAP financial measure. Please see "Non-GAAP Financial Information" and the end of this press release for a reconciliation of Adjusted EBITDA to net income (loss), the most directly comparable financial measure prepared in accordance with GAAP.

<sup>2</sup>A reconciliation of the foregoing guidance for the non-GAAP metric of Adjusted EBITDA to GAAP net income (loss) cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

------

**Webcast and Conference Call Details**

The Company will host a conference call today, October 28<sup>th</sup> at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online.

A live and archived webcast of the event will be available on the "Events & Presentations" section of the BrightSpring website at https://ir.brightspringhealth.com/. The Company has posted supplemental information on the third quarter 2025 results that it will reference during the conference call. The supplemental information can be found under the "Events & Presentations" on the Company's investor relations page.

**About BrightSpring Health Services** 

BrightSpring Health Services provides complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the Company's service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive and more integrated care and clinical solutions in all 50 states to over 460,000 customers, clients and patients daily. BrightSpring has consistently demonstrated strong and often industry-leading quality metrics across its services lines, while improving the quality of life and health for high-need individuals and reducing overall costs to the healthcare system.

**Forward-Looking Statements**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, we have used words such as "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," "target," "guidance," the negative version of these words, or similar terms and phrases to identify these forward-looking statements.

The forward-looking statements are based on management's current expectations and are not historical facts or guarantees of future performance. The forward-looking statements relate to the future and are therefore subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our operation in a highly competitive industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our inability to maintain relationships with existing patient referral sources or establish new referral sources;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•cost containment initiatives of third-party payors, including post-payment audits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our reliance on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, which may negatively impact our profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•reliance on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•compliance with or changes to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•fluctuation of our results of operations on a quarterly basis;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•harm caused by labor relation matters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•limitations in our ability to control reimbursement rates received for our services if we are unable to maintain or reduce our costs to provide such services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•delays in collection or non-collection of our accounts receivable, particularly during the business integration process;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•failure to manage our growth effectively, which may inhibit our ability to execute our business plan, maintain high levels of service and satisfaction or adequately address competitive challenges;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to identify, successfully complete and manage acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to continue to provide consistently high quality of care;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•maintenance of our corporate reputation or the emergence of adverse publicity, including negative information on social media or changes in public perception of our services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•contract continuance, expansion and renewal with our existing customers, including renewals at lower fee levels, customers declining to purchase additional services from us, or reduction in the services received from us pursuant to those contracts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•effective investment in, implementation of improvements to and proper maintenance of the uninterrupted operation and data integrity of our information technology and other business systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•security breaches, loss of data, and other disruptions, which could compromise sensitive business or patient information; cause a loss of confidential patient data, employee data or personal information; or prevent access to critical information and thereby expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•risks related to credit card payments and other payment methods;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•potential substantial malpractice or other similar claims;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits, which may not be entirely covered by insurance;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our current insurance program, which may expose us to unexpected costs, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•factors outside of our control, including those listed, which have required and could in the future require us to record an asset impairment of goodwill;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•a pandemic, epidemic, or outbreak of an infectious disease;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our inability to adequately protect our intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•risks related to our compliance with our regulatory framework;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the interests of KKR Stockholder may conflict with our stockholders' interests in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our substantial indebtedness;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•significant changes in tax or trade policies, tariffs, or trade relations between the United States and other countries, such as the imposition of unilateral tariffs on imported products, including impacts on imported drug products, which could result in supply chain disruptions and significant increases in costs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•repurchases of our common stock.

The forward-looking statements included in this press release are made only as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as required by law. These factors should not be construed as exhaustive, and should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward- looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make.

For additional information on these and other factors that could cause BrightSpring's actual results to differ materially from expected results, please see our filings with the Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.

**Non-GAAP Financial Measures**

This press release contains "non-GAAP financial measures," including "EBITDA," "Adjusted EBITDA," and "Adjusted EPS," which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with accounting principles generally accepted in the United States, or GAAP.

EBITDA, Adjusted EBITDA, and Adjusted EPS have been presented in this release as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP, because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management also believes that these measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses EBITDA, Adjusted EBITDA, and Adjusted EPS to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures.

Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone. EBITDA, Adjusted EBITDA,

------

and Adjusted EPS are not GAAP measures of our financial performance and should not be considered as an alternative to net income (loss) as a measure of financial performance or any other performance measures derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as tax payments, debt service requirements, total capital expenditures, and certain other cash costs that may recur in the future.

Management defines EBITDA as net income (loss) from continuing operations before income tax expense (benefit), interest expense, net and depreciation and amortization. Management also defines Adjusted EBITDA as EBITDA, further adjusted to exclude non-cash share-based compensation, acquisition, integration and transaction-related costs, restructuring and divestiture-related and other costs, legal costs and settlements associated with certain historical matters for PharMerica, significant projects, and management fees.

The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. Please see the end of this press release for reconciliations of non-GAAP financial measures to the most directly comparable financial measure prepared in accordance with GAAP.

**BrightSpring Contact:**

***Investor Relations:***

*David Deuchler, CFA*

*Gilmartin Group LLC*

*ir@brightspringhealth.com*

***Media Contact:***<br> *Leigh White<br>leigh.white@brightspringhealth.com<br>502.630.7412*

------

**BrightSpring Health Services, Inc. and Subsidiaries**

**Consolidated Balance Sheets**

**September 30, 2025 and December 31, 2024**

*(In thousands, except share and per share data)*

*(Unaudited)*

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| **Current assets:** |  |  |
| Cash and cash equivalents | $140344 | $60954 |
| Accounts receivable, net of allowance for credit losses | 1012913 | 902782 |
| Inventories | 639195 | 636561 |
| Prepaid expenses and other current assets | 123978 | 161310 |
| Current assets held for sale | 863846 | 131447 |
| **Total current assets** | 2780276 | 1893054 |
| Property and equipment, net of accumulated depreciation of $387,921 and $339,892 at <br>&nbsp;&nbsp;&nbsp;&nbsp;September 30, 2025 and December 31, 2024, respectively | 175494 | 180570 |
| Goodwill | 2370566 | 2363884 |
| Intangible assets, net of accumulated amortization | 521610 | 595224 |
| Operating lease right-of-use assets, net | 159589 | 161032 |
| Deferred income taxes, net |  | 5288 |
| Other assets | 41962 | 39128 |
| Non-current assets held for sale |  | 687960 |
| **Total assets** | $6049497 | $5926140 |
| **Liabilities, Redeemable Noncontrolling Interest, and Equity** |  |  |
| **Current liabilities:** |  |  |
| Trade accounts payable | $954497 | $923926 |
| Accrued expenses | 304046 | 295746 |
| Current portion of obligations under operating leases | 38217 | 38910 |
| Current portion of obligations under financing leases | 4727 | 3463 |
| Current portion of long-term debt | 51870 | 48725 |
| Current liabilities held for sale | 196613 | 117563 |
| **Total current liabilities** | 1549970 | 1428333 |
| Obligations under operating leases, net of current portion | 128751 | 129467 |
| Obligations under financing leases, net of current portion | 10423 | 6530 |
| Long-term debt, net of current portion | 2465334 | 2561858 |
| Deferred income taxes, net | 10441 |  |
| Long-term liabilities | 63560 | 71190 |
| Non-current liabilities held for sale |  | 77177 |
| **Total liabilities** | 4228479 | 4274555 |
| Redeemable noncontrolling interest | 2361 | 3730 |
| **Shareholders' equity:** |  |  |
| Common stock, $0.01 par value, 1,500,000,000 shares authorized, 180,685,884 and<br> 174,245,990 shares issued and outstanding at September 30, 2025 and <br> December 31, 2024, respectively | $1807 | $1742 |
| Preferred stock, $0.01 par value, 250,000,000 authorized, no shares issued and <br> outstanding at September 30, 2025 and December 31, 2024 |  |  |
| Additional paid-in capital | 1931616 | 1866850 |
| Accumulated deficit | (108569) | (222155) |
| Accumulated other comprehensive (loss) income | (6291) | 1418 |
| Total shareholders' equity | 1818563 | 1647855 |
| Noncontrolling interest | 94 |  |
| **Total equity** | 1818657 | 1647855 |
| **Total liabilities, redeemable noncontrolling interest, and equity** | $6049497 | $5926140 |

---

------

**BrightSpring Health Services, Inc. and Subsidiaries**

**Consolidated Statements of Operations**

**For the three and nine months ended September 30, 2025 and 2024**

*(In thousands, except per share amounts)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues: |  |  |  |  |
| Products | $2966966 | $2265697 | $8289238 | $6357223 |
| Services | 367140 | 335532 | 1070695 | 968026 |
| Total revenues | 3334106 | 2601229 | 9359933 | 7325249 |
| Cost of goods | 2721314 | 2077121 | 7605931 | 5815981 |
| Cost of services | 220784 | 201016 | 648773 | 581509 |
| Gross profit | 392008 | 323092 | 1105229 | 927759 |
| Selling, general, and administrative expenses | 304165 | 293995 | 918090 | 875344 |
| Operating income | 87843 | 29097 | 187139 | 52415 |
| Loss on extinguishment of debt |  |  |  | 12726 |
| Interest expense, net | 38235 | 46614 | 118776 | 144366 |
| Income (loss) from continuing operations before income taxes | 49608 | (17517) | 68363 | (104677) |
| Income tax expense (benefit) | 12120 | 8155 | 13118 | (31464) |
| Income (loss) from continuing operations, net of income taxes | 37488 | (25672) | 55245 | (73213) |
| Income from discontinued operations, net of income taxes | 17753 | 16691 | 56548 | 37288 |
| Net income (loss) | 55241 | (8981) | 111793 | (35925) |
| Net loss attributable to noncontrolling interests included in <br> continuing operations | (595) | (751) | (1793) | (1864) |
| Net income (loss) attributable to BrightSpring Health Services, <br>&nbsp;&nbsp;&nbsp;&nbsp;Inc. and subsidiaries | $55836 | $(8230) | $113586 | $(34061) |
| Net income (loss) per common share: |  |  |  |  |
| Basic income (loss) per share attributable to common shareholders: |  |  |  |  |
| Continuing operations | $0.19 | $(0.13) | $0.28 | $(0.37) |
| Discontinued operations | $0.08 | $0.09 | $0.28 | $0.19 |
| Net income (loss) | $0.27 | $(0.04) | $0.56 | $(0.18) |
| Diluted income (loss) per share attributable to common shareholders: |  |  |  |  |
| Continuing operations | $0.17 | $(0.13) | $0.26 | $(0.37) |
| Discontinued operations | $0.09 | $0.09 | $0.26 | $0.19 |
| Net income (loss) | $0.26 | $(0.04) | $0.52 | $(0.18) |
| Weighted average shares outstanding: |  |  |  |  |
| Basic | 203487 | 198491 | 202067 | 190541 |
| Diluted | 217982 | 198491 | 218519 | 190541 |

---

------

**BrightSpring Health Services, Inc. and Subsidiaries**

**Consolidated Statements of Cash Flows** 

**For the three and nine months ended September 30, 2025 and 2024**

*(In thousands)*

*(Unaudited)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Operating activities:** |  |  |  |  |
| Net income (loss) | $55241 | $(8981) | $111793 | $(35925) |
| Adjustments to reconcile net income (loss) to cash provided by (used in) <br> operating activities: |  |  |  |  |
| Depreciation and amortization | 40753 | 50608 | 124753 | 149601 |
| Impairment of long-lived assets | 2507 | 2801 | 6526 | 4781 |
| Change in fair value of contingent consideration, net | (3269) |  | (1266) |  |
| Payment of contingent consideration in excess of acquisition date fair value | (4670) |  | (6170) |  |
| Provision for credit losses | 8065 | 8778 | 48723 | 21896 |
| Amortization of deferred debt issuance costs | 2841 | 2540 | 8384 | 9477 |
| Share-based compensation | 17250 | 15210 | 55733 | 55194 |
| Deferred income taxes, net | 14374 | 21479 | 18266 | (27781) |
| Loss on extinguishment of debt |  |  |  | 12726 |
| Loss (gain) on disposition of fixed assets | 342 | (79) | 1503 | (55) |
| Other | (416) | 479 | (1838) | (959) |
| Change in operating assets and liabilities, net of acquisitions: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (49933) | (51474) | (162689) | (163996) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 446 | (24207) | 24857 | (2470) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (13752) | (103985) | (2279) | (74265) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable | (10441) | 114234 | 42836 | 155563 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 60702 | 3860 | 17212 | (150032) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (12104) | (4017) | (27734) | (20593) |
| &nbsp;&nbsp;&nbsp;&nbsp; Net cash provided by (used in) operating activities | $107936 | $27246 | $258610 | $(66838) |
| **Investing activities:** |  |  |  |  |
| Purchases of property and equipment | $(15762) | $(20043) | $(57819) | $(65602) |
| Acquisitions of businesses | (1554) | (16144) | (8308) | (59755) |
| Other | (6445) | 360 | (5068) | 900 |
| Net cash used in investing activities | $(23761) | $(35827) | $(71195) | $(124457) |
| **Financing activities:** |  |  |  |  |
| Long-term debt borrowings | $— | $— | $— | $2566000 |
| Long-term debt repayments | (14213) | (13663) | (37933) | (3384633) |
| Proceeds from issuance of common stock on initial public offering, net |  |  |  | 656485 |
| Proceeds from issuance of tangible equity units, net |  |  |  | 389000 |
| Borrowings (repayments) of the Revolving Credit Facility, net |  | 41300 | (63300) | 46400 |
| Payments of debt issuance costs |  |  |  | (43188) |
| Repurchase of shares of common stock |  |  |  | (650) |
| Proceeds from shares issued under share-based compensation plan | 5619 | 127 | 14681 | 531 |
| Taxes paid related to net share settlement of equity awards | (1071) |  | (5583) |  |
| Shares issued for payment of acquisition |  | (1081) |  |  |
| Payment of acquisition earn-outs |  | (1500) |  | (4156) |
| Purchase of redeemable noncontrolling interest |  | (2016) | (5100) | (2316) |
| Payments of financing lease obligations | (3442) | (3640) | (10133) | (9276) |
| Net cash (used in) provided by financing activities | $(13107) | $19527 | $(107368) | $214197 |
| Net increase in cash and cash equivalents | 71068 | 10946 | 80047 | 22902 |
| Cash and cash equivalents at beginning of period | 70232 | 25027 | 61253 | 13071 |
| Cash and cash equivalents at end of period | $141300 | $35973 | $141300 | $35973 |
| Cash and cash equivalents included in assets held for sale at end of period | 956 | 427 | 956 | 427 |
| Cash and cash equivalents included in continuing operations at end of period | $140344 | $35546 | $140344 | $35546 |

---

------

**BrightSpring Health Services, Inc. and Subsidiaries**

**Reconciliation of EBITDA and Adjusted EBITDA**

**For the three and nine months ended September 30, 2025 and 2024**

*(Unaudited)*

The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *($ in thousands)* | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net income (loss) | $37488 | $(25672) | $55245 | $(73213) |
| Income tax expense (benefit) | 12120 | 8155 | 13118 | (31464) |
| Interest expense, net | 38235 | 46614 | 118776 | 144366 |
| Depreciation and amortization | 40753 | 40533 | 123424 | 119469 |
| EBITDA | $128596 | $69630 | $310563 | $159158 |
| Non-cash share-based compensation (1) | 14173 | 12720 | 46155 | 49793 |
| Acquisition, integration, and transaction-related costs (2) | 5462 | 11766 | 34811 | 25328 |
| Restructuring and divestiture-related and other costs (3) | 12212 | 12904 | 42493 | 47642 |
| Legal costs and settlements (4) |  | 8920 |  | 21886 |
| Significant projects (5) |  | 1000 |  | 2604 |
| Management fee (6) |  |  |  | 23381 |
| Total adjustments | $31847 | $47310 | $123459 | $170634 |
| Adjusted EBITDA | $160443 | $116940 | $434022 | $329792 |

---

(1)Represents non-cash share-based compensation to certain members of our management and full-time employees. The nine months ended September 30, 2024 includes $15.0 million of previously unrecognized share-based compensation expense related to performance-vesting options under the 2017 Stock Plan, a portion of which vested upon completion of the IPO.

(2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, finance and accounting diligence and documentation; costs associated with the integration of acquisitions, including any facility consolidation, integration travel, or severance; and costs associated with other planned, completed, or terminated non-routine transactions. The three and nine months ended September 30, 2025 includes other non-routine transaction costs of $1.1 million and $23.4 million, respectively, as compared to $0.7 and $1.4 million in the three and nine months ended September 30, 2024.

(3)Represents costs associated with restructuring-related activities, including closure, and related license impairment, and severance expenses associated with certain enterprise-wide or significant business line cost-savings measures. These costs include $3.8 million and $18.5 million of costs that did not meet the criteria for discontinued operations related to the Community Living divestiture for the three and nine months ended September 30, 2025, respectively, as compared to $6.2 million and $19.6 million for the three and nine months ended September 30, 2024, respectively. These costs also include $12.7 million of unamortized debt issuance costs associated with the extinguishment of our Second Lien Facility in the nine months ended September 30, 2024.

(4)Represents settlement and defense costs associated with certain historical PharMerica litigation matters, including the Silver matter, all of which were finalized in 2024. See Note 13 within the unaudited condensed consolidated financial statements and related notes in this Quarterly Report on Form 10-Q for additional information.

(5)Represents costs associated with certain transformational projects and for the periods presented primarily included general ledger system implementation, pharmacy billing system implementation, and ransomware attack response costs, all of which were finalized in 2024.

(6)Represents annual management fees payable to the Managers under the Monitoring Agreement through the date of the IPO, and $22.7 million of termination fees resulting from the termination of the Monitoring Agreement upon completion of the IPO Offerings. All management fees ceased following the completion of the IPO in 2024.

------

**BrightSpring Health Services, Inc. and Subsidiaries**

**Reconciliation of Adjusted EPS**

**For the three and nine months ended September 30, 2025 and 2024**

*(Unaudited)*

The following table reconciles diluted EPS to Adjusted EPS:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(shares in thousands)* | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Diluted EPS | $0.17 | $(0.13) | $0.26 | $(0.37) |
| Non-cash share-based compensation (1) | 0.07 | 0.06 | 0.21 | 0.25 |
| Acquisition, integration, and transaction-related costs (1) | 0.03 | 0.06 | 0.16 | 0.13 |
| Restructuring and divestiture-related and other costs (1) | 0.06 | 0.06 | 0.19 | 0.24 |
| Legal costs and settlements (1) |  | 0.04 |  | 0.11 |
| Significant projects (1) |  | 0.00 |  | 0.01 |
| Management fee (1) |  |  |  | 0.12 |
| Income tax impact on adjustments (2)(3) | (0.03) | (0.06) | (0.13) | (0.29) |
| Adjusted EPS | $0.30 | $0.03 | $0.69 | $0.20 |
| Weighted average common shares outstanding used in <br>&nbsp;&nbsp;&nbsp;&nbsp; calculating diluted U.S. GAAP net income (loss) per share | 217982 | 198491 | 218519 | 190541 |
| Weighted average common shares outstanding used in <br>&nbsp;&nbsp;&nbsp;&nbsp; calculating diluted Non-GAAP income per share | 217982 | 208694 | 218519 | 199930 |

---

(1)This adjustment reflects the per share impact of the adjustment reflected within the definition of Adjusted EBITDA.

(2)The income tax impact of non-GAAP adjustments is calculated using the estimated tax rate for the respective non-GAAP adjustment.

(3)For the three and nine months ended September 30, 2024, the income tax impact on adjustments is inclusive of a discrete tax benefit related to the Silver matter that was finalized in connection with the signing of the settlement agreement during the second fiscal quarter of 2024.

------